Antiviral activity of Carbenoxolone disodium against dengue virus infection
Jieying Pua b c d, Li Hea b c d e f, Heping Xieg h, Siyu Wua b c d, Yu‐Ye Lia b c d, Ping Zhanga c, Zhicong Yangi j✉, Xi Huanga b c d✉
- aKey Laboratory of Tropical Diseases Control (Sun Yat‐sen University) Ministry of Education Guangzhou China
- bProgram of Immunology, Affiliated Guangzhou Women and Children's Medical Center, Zhongshan School of Medicine Sun Yat‐sen University Guangzhou China
- cKey Laboratory of Tropical Diseases Control (Sun Yat-sen University), Ministry of Education, Guangzhou, China
- dProgram of Immunology, Affiliated Guangzhou Women and Children's Medical Center, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China
- eThe First College of Clinical Medical Science China Three Gorges University Yichang China
- fThe First College of Clinical Medical Science, China Three Gorges University, Yichang, China
- gDepartment of Traditional Chinese Medicine Third Affiliated Hospital Sun Yat‐sen University Guangzhou China
- hDepartment of Traditional Chinese Medicine, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
- iGuangzhou Center for Disease Control and Prevention Guangzhou China
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
As one of the most important mosquito-borne viral diseases, dengue infection is now becoming a global concern due to its rapid spread and rise in incidence. Currently, there is no approved vaccine or effective antiviral drug for dengue virus (DENV) infection. Glycyrrhetinic acid (GNa) and its related derivatives have been reported to inhibit a broad spectrum of viruses. However, it is unknown whether Carbenoxolone disodium (CBX), one of the GNa derivatives, affects DENV infection. Here, we found that the production of infectious DENV particles was significantly decreased by CBX treatment in DENV-permissive cells, while the viral RNA and viral protein synthesis were not affected. Moreover, results from time-of-addition study showed that the inhibitory effect of CBX on DENV was exhibited by targeting the virus itself, not the host cells. Directly incubating DENV with CBX resulted in a remarkable reduction of virus titer and virus infectivity. Furthermore, DENV RNA from progeny virions in the supernatants was significantly decreased by CBX treatment in a dose-dependent manner. Taken together, these data indicate that the antiviral activity of CBX against DENV may be mainly due to a virucidal effect exerted by the compound itself. Our work, for the first time, demonstrates that CBX has antiviral activity against DENV infection, providing useful information for development of potential therapeutic interventions against dengue. J. Med. Virol. 89:571-581, 2017. © 2016 Wiley Periodicals, Inc.
TL;DRIt is demonstrated for the first time that CBX has antiviral activity against DENV infection, providing useful information for development of potential therapeutic interventions against dengue. (Semantic Scholar)